MeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. It focuses on the development and manufacturing of genetic medicines to treat both inherited and more common conditions with severe unmet need. The company was founded on March 20, 2015 and is headquartered in New York, NY.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company